Filing Scope and Business Context
The provided filing is Selecta Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, not a filing for Cartesian Therapeutics, Inc. The filing covers the full 2017 fiscal year and includes unaudited quarterly data for the fourth quarter. Selecta is a clinical-stage biopharmaceutical company developing synthetic vaccine particle technology intended to induce immune tolerance or stimulate immune responses.
The lead program was SEL-212, a combination of SVP-Rapamycin and pegsiticase for chronic severe gout. SEL-212 was in Phase 2 development, while SEL-403 for mesothelioma and SELA-070 for smoking cessation were in Phase 1 development. Gene therapy programs, including SEL-302 for methylmalonic acidemia, remained preclinical.
Key Financial Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Grant and collaboration revenue | $0.2 million | $8.1 million | Down 97% |
| Research and development expense | $45.2 million | $29.7 million | Up 52% |
| General and administrative expense | $18.8 million | $13.1 million | Up 44% |
| Total operating expenses | $64.0 million | $42.8 million | Up 50% |
| Loss from operations | $63.8 million | $34.7 million | Higher loss |
| Net loss | $65.3 million | $36.2 million | Higher loss |
| Basic and diluted loss per share | $3.20 | $3.89 | Improved due primarily to share count growth |
| Net cash used in operating activities | $52.0 million | $19.7 million | Higher use |
Fourth-quarter 2017 revenue was $17,000, operating expenses were $19.3 million, and net loss was $19.5 million, or $0.88 per share. The filing does not provide a separate fourth-quarter margin measure; the company was loss-making at the operating and net levels.
At December 31, 2017, cash and cash equivalents were $70.6 million, short-term deposits and investments were $25.9 million, and restricted cash was approximately $0.4 million. Total assets were $101.1 million, total liabilities were $49.3 million, and stockholders’ equity was $51.8 million. The accumulated deficit was $216.9 million.
Loans payable, net of the current portion, were $21.0 million. The company entered into a $21.0 million Silicon Valley Bank term loan in September 2017, used $10.0 million to repay the prior term loan, and had approximately $25.1 million of scheduled principal and interest payments remaining at year-end. The loan matures in February 2022, has interest-only payments through August 2019, and is secured by substantially all assets other than intellectual property, with related restrictions and default provisions.
Material Changes Versus the Prior Comparable Period
- Revenue declined by $7.9 million because nicotine vaccine grant activity wound down and the Sanofi collaboration had been terminated.
- Research and development spending increased $15.5 million, principally due to the Phase 2 SEL-212 trial, Phase 3 planning, discovery and preclinical programs, headcount, facilities, and other development costs.
- General and administrative expense increased $5.8 million due to headcount growth, public-company compliance, professional fees, licensing costs, stock compensation, and facilities expenses.
- Net loss increased by $29.1 million to $65.3 million, while operating cash use increased by $32.4 million to $52.0 million.
- Financing activities provided $66.0 million, including $47.1 million of net proceeds from a June 2017 private placement, $20.9 million of net term-loan proceeds, and $10.0 million from stock issued to Spark Therapeutics, partially offset by debt repayments.
- The company licensed LMB-100 from the National Cancer Institute and advanced its immunotoxin program toward the SEL-403 Phase 1 trial, which began in March 2018 after the reporting period.
- The company expanded its collaboration with Spark Therapeutics. Spark had paid $30.0 million in aggregate under the license arrangement as described in the filing and could become obligated for substantial development and commercial milestones, royalties, and additional option fees; the arrangement also generated $14.7 million of deferred revenue at year-end.
Guidance, Outlook, Risks, and Unusual Items
Management stated that existing cash, cash equivalents, investments, and restricted cash were expected to fund operating expenses and capital expenditures into mid-2019, based on the company’s then-current operating plan. Management also stated that substantial additional funding would be required and that no committed external liquidity source existed apart from potential collaborator reimbursements and milestone payments.
- The company expected continuing and increasing losses until, if ever, product revenues were generated.
- Management planned to continue advancing SEL-212, including preparation for a Phase 3 program, while funding other clinical and preclinical programs.
- SEL-212 clinical data suggested dose-dependent uric-acid control and reduced anti-drug antibodies, but the results were from early-stage, small or non-head-to-head studies and were not evidence of regulatory approval or commercial success.
- Reported SEL-212 safety findings included serious adverse events, including stomatitis at the highest SVP-Rapamycin dose and a drug hypersensitivity event; the filing stated that all reported events resolved.
- Key risks included the unproven SVP technology, clinical-trial failure or delays, regulatory uncertainty, patient enrollment, manufacturing and supply dependence on 3SBio in China, intellectual-property challenges, reimbursement uncertainty, competition, and the need for additional capital.
- The company relied heavily on third-party manufacturers and clinical research providers and had no commercial-scale manufacturing experience.
- The September 2017 debt refinancing produced a $0.7 million loss on extinguishment of debt.
- The Tax Cuts and Jobs Act caused a provisional $23.4 million reduction in deferred tax assets, fully offset by the valuation allowance, with no net tax effect reported.
- CEO Werner Cautreels announced in January 2018 that he intended to retire effective December 31, 2018, creating a leadership-transition risk.
- The filing reported no material legal proceedings and no off-balance-sheet arrangements.
Investor Verification Priorities
- Confirm the issuer identity: the supplied document is for Selecta Biosciences, Inc., whereas the request identifies Cartesian Therapeutics, Inc.
- Verify the timing and sufficiency of liquidity, including the mid-2019 cash runway estimate and the need for additional equity, debt, grant, or collaboration funding.
- Review SEL-212 Phase 2 results, safety data, statistical robustness, Phase 3 design, and the FDA’s requirements before relying on management’s development outlook.
- Assess the terms, collateral, interest rate, covenants, repayment schedule, and acceleration provisions of the Silicon Valley Bank term loan.
- Evaluate revenue concentration and the effect of the terminated Sanofi collaboration, remaining Spark obligations, deferred revenue, and potential milestone uncertainty.
- Assess dependence on 3SBio for pegsiticase supply and the regulatory implications of biologic manufacturing in China.
- Review dilution exposure from outstanding options, warrants, future capital raises, the $50 million ATM facility, and collaboration-related equity issuances.
- Verify the planned CEO succession and its potential effect on clinical execution, financing, and strategic priorities.